EP3 receptor is a prognostic factor in TA-MUC1-negative ovarian cancer.
EP3
Gatipotuzumab
Ovarian cancer
Prognostic factor
TA-MUC1
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
10
08
2019
accepted:
30
08
2019
pubmed:
6
9
2019
medline:
8
10
2019
entrez:
6
9
2019
Statut:
ppublish
Résumé
Prostaglandin-mediated inflammatory reactions play a major role in different cancers. Recently, it has been observed that prostaglandin E2-receptor 3 (EP3) might be an independent prognostic factor for overall survival in cervical and endometrial cancer. The role of EP3 expression in ovarian cancer is currently unknown. EP3 expression was analyzed by immunohistochemistry in 156 patient samples using the IR-scoring system. Expression levels were correlated with clinical and pathological parameters and with overall survival (OS) to assess for prognostic relevance. Data analysis was performed using Spearman's correlations, Kruskal-Wallis test and Kaplan-Meier estimates. EP3 expression was significantly higher in clear-cell carcinoma (p < 0.001) compared to the other histological subtypes. No further correlations with clinical parameters could be found. EP3 expression correlated significantly with FSH-receptor expression (p < 0.001), galectin-1 expression in the tumor (p = 0.012) and with cytoplasmatic TA-MUC1 expression (p = 0.001). None of these parameters showed significant correlation with OS. In the TA-MUC1 negative subgroup, EP3 negative patients showed significantly longer OS (median OS: 102 months vs. 34 months in EP3 positive patients, p = 0.035), while EP3 did not appear to have prognostic relevance in the TA-MUC1-positive subgroup. The potential prognostic relevance of EP3 expression for OS in TA-MUC1 negative patients might reflect an interplay between the COX and the MUC1 pathway, as it has been shown that MUC1 could induce COX2 expression. Our findings support the importance of the prostanoid signaling in TA-MUC1 negative ovarian cancer; however, future studies are necessary to characterize specific pathways and possible interactions.
Identifiants
pubmed: 31485769
doi: 10.1007/s00432-019-03017-8
pii: 10.1007/s00432-019-03017-8
doi:
Substances chimiques
Biomarkers, Tumor
0
MUC1 protein, human
0
Mucin-1
0
PTGER3 protein, human
0
Receptors, Prostaglandin E, EP3 Subtype
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2519-2527Références
Aletti GD, Gostout BS, Podratz KC, Cliby WA (2006) Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol Oncol 100(1):33–37
doi: 10.1016/j.ygyno.2005.07.123
pubmed: 16153692
Ali-Fehmi R, Morris RT, Bandyopadhyay S, Che M, Schimp V, Malone JM Jr et al (2005) Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival. Am J Obstet Gynecol 192(3):819–825
doi: 10.1016/j.ajog.2004.10.587
pubmed: 15746677
Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I et al (2012) Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol 120(3):612–618
doi: 10.1097/AOG.0b013e318264f794
pubmed: 22914471
Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K et al (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355(9):873–884
doi: 10.1056/NEJMoa061355
pubmed: 16943400
Chetry M, Thapa S, Hu X, Song Y, Zhang J, Zhu H et al (2018) The Role of galectins in tumor progression, treatment and prognosis of gynecological cancers. J Cancer 9(24):4742–4755
doi: 10.7150/jca.23628
pubmed: 30588260
pmcid: 6299382
Dembo AJ, Davy M, Stenwig AE, Berle EJ, Bush RS, Kjorstad K (1990) Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol 75(2):263–273
pubmed: 2300355
Dian D, Lenhard M, Mayr D, Heublein S, Karsten U, Goletz S et al (2013) Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX detecting the tumour-associated epitope, TA-MUC1, as compared to antibodies HMFG-1 and 115D8. Histol Histopathol 28(2):239–244
pubmed: 23275306
du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 115(6):1234–1244
doi: 10.1002/cncr.24149
pubmed: 19189349
Emons G, Pahwa GS, Ortmann O, Knuppen R, Oberheuser F, Schulz KD (1990) LHRH-receptors and LHRH-agonist treatment in ovarian cancer: an overview. J Steroid Biochem Mol Biol 37(6):1003–1006
doi: 10.1016/0960-0760(90)90457-V
pubmed: 2178360
Harris RE (2009) Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 17(2):55–67
doi: 10.1007/s10787-009-8049-8
pubmed: 19340409
Heidegger H, Dietlmeier S, Ye Y, Kuhn C, Vattai A, Aberl C et al (2017) The prostaglandin EP3 receptor is an independent negative prognostic factor for cervical cancer patients. Int J Mol Sci 18(7):1571. https://doi.org/10.3390/ijms18071571
doi: 10.3390/ijms18071571
pmcid: 5536059
Heublein S, Page S, Mayr D, Schmoeckel E, Trillsch F, Marme F et al (2019) Potential interplay of the gatipotuzumab epitope TA-MUC1 and estrogen receptors in ovarian cancer. Int J Mol Sci 20(2):295. https://doi.org/10.3390/ijms20020295
doi: 10.3390/ijms20020295
pmcid: 6359481
Hou R, Jiang L, Liu D, Lin B, Hu Z, Gao J et al (2017) Lewis(y) antigen promotes the progression of epithelial ovarian cancer by stimulating MUC1 expression. Int J Mol Med 40(2):293–302
doi: 10.3892/ijmm.2017.3009
pubmed: 28586014
pmcid: 5504979
Howe LR (2007) Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res 9(4):210
doi: 10.1186/bcr1678
pubmed: 17640394
pmcid: 2206709
Kossai M, Leary A, Scoazec JY, Genestie C (2018) Ovarian cancer: a heterogeneous disease. Pathobiology 85(1–2):41–49
doi: 10.1159/000479006
pubmed: 29020678
Ledermann J, Sehouli J, Zurawski B, Raspagliesi F, De Giorgi U, Banerjee S et al (2017) LBA41A double-blind, placebo-controlled, randomized, phase 2 study to evaluate the efficacy and safety of switch maintenance therapy with the anti-TA-MUC1 antibody PankoMab-GEX after chemotherapy in patients with recurrent epithelial ovarian carcinoma. Ann Oncol 28(suppl_8):viii46–viii50
doi: 10.1093/annonc/mdx452
pubmed: 29232475
Matsumura N, Yamamoto M, Aruga A, Takasaki K, Nakano M (2002) Correlation between expression of MUC1 core protein and outcome after surgery in mass-forming intrahepatic cholangiocarcinoma. Cancer 94(6):1770–1776
doi: 10.1002/cncr.10398
pubmed: 11920540
Mukherjee P, Basu GD, Tinder TL, Subramani DB, Bradley JM, Arefayene M et al (2009) Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J Immunol 182(1):216–224
doi: 10.4049/jimmunol.182.1.216
pubmed: 19109152
pmcid: 3838792
Nath S, Roy LD, Grover P, Rao S, Mukherjee P (2015) Mucin 1 regulates Cox-2 gene in pancreatic cancer. Pancreas 44(6):909–917
doi: 10.1097/MPA.0000000000000371
pubmed: 26035123
pmcid: 4500655
Niringiyumukiza JD, Cai H, Xiang W (2018) Prostaglandin E2 involvement in mammalian female fertility: ovulation, fertilization, embryo development and early implantation. Reprod Biol Endocrinol 16(1):43
doi: 10.1186/s12958-018-0359-5
pubmed: 29716588
pmcid: 5928575
Obermajer N, Muthuswamy R, Odunsi K, Edwards RP, Kalinski P (2011) PGE(2)-induced CXCL12 production and CXCR38 expression controls the accumulation of human MDSCs in ovarian cancer environment. Can Res 71(24):7463–7470
doi: 10.1158/0008-5472.CAN-11-2449
Perales-Puchalt A, Svoronos N, Rutkowski MR, Allegrezza MJ, Tesone AJ, Payne KK et al (2017) Follicle-stimulating hormone receptor is expressed by most ovarian cancer subtypes and is a safe and effective immunotherapeutic target. Clin Cancer Res 23(2):441–453
doi: 10.1158/1078-0432.CCR-16-0492
pubmed: 27435394
Rask K, Zhu Y, Wang W, Hedin L, Sundfeldt K (2006) Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. Mol Cancer 5:62
doi: 10.1186/1476-4598-5-62
pubmed: 17107625
pmcid: 1657027
Reader J, Holt D, Fulton A (2011) Prostaglandin E2 EP receptors as therapeutic targets in breast cancer. Cancer Metastasis Rev 30(3–4):449–463
doi: 10.1007/s10555-011-9303-2
pubmed: 22002714
pmcid: 3640271
Rodriguez-Burford C, Barnes MN, Oelschlager DK, Myers RB, Talley LI, Partridge EE et al (2002) Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res 8(1):202–209
pubmed: 11801560
Schulz H, Schmoeckel E, Kuhn C, Hofmann S, Mayr D, Mahner S et al (2017) Galectins-1, -3, and -7 are prognostic markers for survival of ovarian cancer patients. Int J Mol Sci 18(6):1230. https://doi.org/10.3390/ijms18061230
doi: 10.3390/ijms18061230
pmcid: 5486053
Schulz H, Kuhn C, Hofmann S, Mayr D, Mahner S, Jeschke U et al (2018) Overall survival of ovarian cancer patients is determined by expression of galectins-8 and -9. Int J Mol Sci 19(1):323. https://doi.org/10.3390/ijms19010323
doi: 10.3390/ijms19010323
pmcid: 5796266
Semmlinger A, von Schoenfeldt V, Wolf V, Meuter A, Kolben TM, Kolben T et al (2018) EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer. BMC Cancer 18(1):431
doi: 10.1186/s12885-018-4286-9
pubmed: 29661238
pmcid: 5902996
Siegel RL, Miller KD, Jemal A (2019) Cancer statistics. CA Cancer J Clin 69(1):7–34
doi: 10.3322/caac.21551
pubmed: 30620402
pmcid: 30620402
Sugimoto Y, Narumiya S (2007) Prostaglandin E receptors. J Biol Chem 282(16):11613–11617
doi: 10.1074/jbc.R600038200
pubmed: 17329241
Tinder TL, Subramani DB, Basu GD, Bradley JM, Schettini J, Million A et al (2008) MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. J Immunol 181(5):3116–3125
doi: 10.4049/jimmunol.181.5.3116
pubmed: 18713982
pmcid: 2625292
Tsujii M, Kawano S, DuBois RN (1997) Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94(7):3336–3340
doi: 10.1073/pnas.94.7.3336
pubmed: 9096394
Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P et al (2001) Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 357(9251):176–182
doi: 10.1016/S0140-6736(00)03590-X
pubmed: 11213094
Wang D, Dubois RN (2010) Eicosanoids and cancer. Nat Rev Cancer 10(3):181–193
doi: 10.1038/nrc2809
pubmed: 20168319
pmcid: 2898136
Williams CS, Mann M, DuBois RN (1999) The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18(55):7908–7916
doi: 10.1038/sj.onc.1203286
pubmed: 10630643
Ye Y, Vattai A, Ditsch N, Kuhn C, Rahmeh M, Mahner S et al (2018) Prostaglandin E2 receptor 3 signaling is induced in placentas with unexplained recurrent pregnancy losses. Endocr Connect 7(5):749–761
doi: 10.1530/EC-18-0106
pubmed: 29700097
pmcid: 5958745
Zhu J, Trillsch F, Mayr D, Kuhn C, Rahmeh M, Hofmann S et al (2018) Prostaglandin receptor EP3 regulates cell proliferation and migration with impact on survival of endometrial cancer patients. Oncotarget 9(1):982–994
pubmed: 29416671
Zhuandi G, Tuanjie C, Luju L, Abdiryim A, Yingying D, Haoqin L et al (2018) FSH receptor binding inhibitor restrains follicular development and possibly attenuates carcinogenesis of ovarian cancer through down-regulating expression levels of FSHR and ERbeta in normal ovarian tissues. Gene 668:174–181
doi: 10.1016/j.gene.2018.05.068
pubmed: 29783074